| Muck and Mystery Loitering With Intent |
blog - at - crumbtrail.org |
Biocontrol. Or perhaps genetic algorithms.
MIT biologists have provoked soil-dwelling bacteria into producing a new type of antibiotic by pitting them against another strain of bacteria in a battle for survival.The idea of fighting fire with fire, life with life, is an old one that has had spectacular success as well as not infrequent failure. There's no way to predict the outcomes of such conflicts. The combatants have their own agendas and sometimes choose a different path than the one naively hoped for. The attackers, for example, might choose to engage with a different opponent. This has happened with insects introduced to prey on agricultural pests. They find some other target that is easier or more desirable in some other way.The antibiotic holds promise for treatment of Helicobacter pylori, which causes stomach ulcers in humans. Also, figuring out the still murky explanation for how the new antibiotic was produced could help scientists develop strategies for finding other new antibiotics.
Sinskey's lab has been studying Rhodococcus, a type of soil-dwelling bacteria, for many years. While sequencing the genome of one Rhodococcus species, the researchers noticed that a large number of genes seemed to code for secondary metabolic products, which are compounds such as antibiotics, toxins and pigments.The mild mannered, bespectacled Rhodococcus only showed its mettle when threatened by competitors.However, Rhodococcus does not normally produce antibiotics. Many bacteria have genes for antibiotics that are only activated when the bacteria are threatened in some way, so the researchers suspected that might be true of Rhodococcus.
Kazuhiko Kurosawa, a postdoctoral associate in the Department of Biology, decided to try to provoke the bacteria into synthesizing antibiotics by placing them in stressful environments. He tried turning the temperature up and down, then altered the bacteria's growth medium, but nothing worked.
Kurosawa then decided to stress the Rhodococcus bacteria by forcing them to grow in the presence of a competing bacteria, a strain of Streptomyces. Streptomyces produces an antibiotic that normally kills other bacteria, but in one of the experimental test tubes, Rhodococcus started producing its own antibiotic, which wiped out the Streptomyces.
The antibiotic turned out to be a type of molecule called an aminoglycoside, composed of peculiar sugars, one of which has a ring structure that has not been seen before. The ring structure could offer chemists a new target for modification, allowing them to synthesize antibiotics that are more effective and/or stable.A new clue!
One mystery still to be solved is why Rhodococcus started producing this antibiotic. One theory is that the presence of the competing strain of bacteria caused Rhodococcus to “raise the alarm” and turn on new genes.Miscegenation. I sometimes get an image of microbial life as a tool kit one could use to construct most anything, even us, if we understood it well and used it with skill. Or perhaps it isn't the tool kit so much as the instruction manual: how to own and operate a universe, or the care and feeding of life, depending on POV and temperament.The version of Rhodococcus that produces the antibiotic has a “megaplasmid,” or large segment of extra DNA, that it received from Streptomyces. A logical conclusion is that the plasmid carries the gene for rhodostreptomycin, but the researchers have sequenced more than half of the plasmid and found no genes that correlate to the antibiotic.
Another theory is that the plasmid itself served as the “insult” that provoked Rhodococcus into producing the antibiotic. Alternatively, it is possible that some kind of interaction of the two bacterial genomes produced the new antibiotic.
“Somehow the genes in the megaplasmid combined with the genes in Rhodococcus and together they produced something that neither parent could make alone,” said Lessard.
If scientists could figure out how that happens, they could start to manipulate bacterial genomes in a more methodical fashion to design new antibiotics.